Oncimmune Holdings Management

Management Kriterienprüfungen 2/4

Oncimmune Holdings' CEO ist Martin Gouldstone , ernannt in Aug 2023, hat eine Amtszeit von weniger als ein Jahr. besitzt direkt 0.049% der Aktien des Unternehmens, im Wert von £5.49K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.4 Jahre bzw. 5.2 Jahre.

Wichtige Informationen

Martin Gouldstone

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	less than a year
Eigentum des Geschäftsführers	0.05%
Durchschnittliche Amtszeit des Managements	4.4yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.2yrs

Jüngste Management Updates

Recent updates

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Aug 16

Geschäftsführer

Martin Gouldstone (58 yo)

less than a year

Amtszeit

Mr. Martin John Gouldstone is Chief Executive Officer and Director of Oncimmune Holdings plc from August 1, 2023. He serves as an Independent Non-Executive Director of ValiRx Plc since April 22, 2024. He i...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Martin Gouldstone	CEO & Director	less than a year	keine Daten	0.049% £ 4.0k
Martin Hudson	Finance Director	less than a year	keine Daten	keine Daten
Ron Kirschner	COO, General Counsel & Company Secretary	4.2yrs	keine Daten	0.0022% £ 184.3
Tariq Sethi	Chief Scientific Officer	4.7yrs	keine Daten	keine Daten
Cléa Rosenfeld	Head of Investor Relations	4.9yrs	keine Daten	keine Daten
Maarten Brusse	Chief Commercial Officer of Asia	7.8yrs	keine Daten	keine Daten

4.4yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: ONCDas Führungsteam des Unternehmens gilt als erfahren (4.4 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Martin Gouldstone	CEO & Director	less than a year	keine Daten	0.049% £ 4.0k
Alistair Macdonald	Non-executive Chairman	1.9yrs	UK£17.00k	0.075% £ 6.2k
John Goold	Independent Non-Executive Director	1.4yrs	keine Daten	1.55% £ 128.2k
Parag Mallick	Member of Scientific Board	5.2yrs	keine Daten	keine Daten
Richard Roope	Member of Scientific Board	5.5yrs	keine Daten	keine Daten
Nora Pashayan	Member of Scientific Board	5.5yrs	keine Daten	keine Daten
Ola Winqvist	Member of Scientific Board	5.5yrs	keine Daten	keine Daten

5.2yrs

Durchschnittliche Betriebszugehörigkeit

54yo

Durchschnittliches Alter

Erfahrener Vorstand: ONCDie Vorstandsmitglieder gelten als erfahren (5.2 Jahre durchschnittliche Amtszeit).

Oncimmune Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Less than half of directors are independent

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Recent updates

New major risk - Negative shareholders equity

New major risk - Share price stability

Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024

Less than half of directors are independent

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

New major risk - Share price stability

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Estimating The Intrinsic Value Of Oncimmune Holdings plc (LON:ONC)

Oncimmune Holdings plc Announces Board Changes

Price target increased to UK£2.22

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

New 90-day high: UK£1.94

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: UK£1.90

Oncimmune Holdings plc Signs Commercial Contracts

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Annual earnings released: Earnings beat expectations, revenue disappoints

Full year earnings released - UK£0.13 loss per share

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

New 90-day high: UK£1.73

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - UK£1.51

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter